Crenolanib is an orally bioavailable, selective small molecule inhibitor of the Platelet-derived growth factor receptor (PDGFR) tyrosine kinase, inhibiting both purified PDGFRα and PDGFRβ with IC50s of 0.9 nM and 1.8 nM, respectively. It is also a type I pan-FLT3 inhibitor, highly selective over the closely related protein tyrosine kinase KIT, capable of inhibiting both FLT3/ITD and resistance-conferring FLT3/D835 mutants in vivo. It is considered to be an important next-generation FLT3 inhibitor.

KEYWORDS: Crenolanib | Supplier | PDGFRα |  PDGFRβ and FLT3 inhibitor | CP-868596 | ARO-002 | Plarotinib | CP868596 | CP 868596 | ARO002 | ARO 002 | CT-CREN | CAS [670220-88-9] | PDGF | PDGFR | FLT3 | Inhibitor | Receptors